<DOC>
	<DOCNO>NCT03043105</DOCNO>
	<brief_summary>To explore effectiveness safety thalidomide , cyclophosphamide prednisone ( TCP regimen ) newly diagnose Multicentric Castleman 's disease ( MCD ) patient .</brief_summary>
	<brief_title>TCP Regimen Newly Diagnosed MCD : Prospective , Single-center , Single-arm , Phase-II Pilot Trial</brief_title>
	<detailed_description>This single center , open-labeled , single arm , phase-II pilot study aim evaluate efficacy safety thalidomide , cyclophosphamide prednisone ( TCP regimen ) newly diagnose Multicentric Castleman 's disease ( MCD ) patients.There would two phase study . The treatment response evaluation phase last time enrollment 24 month ( evaluation carry every 3 month ) . The follow-up phase ass progression disease last 24 month ( 2 year ) 4 year enrollment ( evaluation carry every 12 month ) .The total study duration 4 year last patient start study medication .</detailed_description>
	<mesh_term>Giant Lymph Node Hyperplasia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>≥18 year , race/ethnic group China； Newly diagnose previously untreated ( patient allow received oral prednisone 1 week enrollment ) symptomatic MCD patient ( symptomatic disease define presence clinical symptom NCICTCAE grade ≥1 attributable disease , treatment indicate ) ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤2 ; Clinical laboratory value meet criterion screening : absolute neutrophil count ≥ 1•0 x 109/L , Platelets ≥ 50 x 109/L , Alanine aminotransferase ( ALT ) within 2•5 x upper limit normal ( ULN ) ; total bilirubin within 2•5 x ULN ; estimate glomerular filtration rate ( accord MDRD formula ) &lt; 15ml/min ; Women childbearing potential must agree use birth control measure study least 3 month receive last dose study agent , must negative pregnancy test screening period . Men must agree use birth control measure study least 3 month receive last dose study agent ; Informed consent must sign . age 18 year ; ECOG ( eastern cooperative oncology group ) status 2 ; Immunosuppressive antineoplastic drug within last 3 month ; serious disease include malignancy ; Plan baby within 1 year enrollment ( woman men ) , pregnancy / breastfeeding ( woman ) ; Known hypersensitivity study agent ; Active infection require systemic treatment ; Other severe concurrent disease ( eg . uncontrolled diabetes , symptomatic coronary heart disease ) likely interfere study procedure result , opinion investigator would constitute hazard participate study ; Unwilling unable provide inform consent ; Unwilling return followup PUMCH .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multicentric Castleman 's Disease</keyword>
	<keyword>Thalidomide , cyclophosphamide prednisone ( TCP regimen )</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>